Eli Lilly announces Phase 2 trial of lepodisiran met primary endpoint

Eli Lilly (LLY) and Company announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA, siRNA, therapy designed to lower the production of lipoprotein, a genetically inherited risk factor for heart disease. In the Phase 2 ALPACA study, lepodisiran significantly reduced Lpa levels by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose, meeting the primary endpoint. Participants who received the 16 mg and 96 mg lepodisiran doses experienced a 40.8% reduction and a 75.2% reduction in Lpa levels over the same time period, respectively. Results from additional secondary endpoints showed: Participants who received 400 mg of lepodisiran at both baseline and day 180 experienced a 94.8% reduction in average Lpa levels over the day 30 to 360 period, which remained 91.0% below baseline at day 360 and 74.2% below baseline at day 540 . Lepodisiran also reduced apolipoprotein B levels, a separate cholesterol biomarker. The highest dose of lepodisiran showed 14.1% and 13.7% ApoB reductions from baseline at day 60 and 180, respectively. A second 400 mg lepodisiran dose at day 180 sustained these apoB reductions through day 540